
MaaT Pharma’s microbiome therapy scores phase 3 win
By Helen Albert
MaaT Pharma’s microbiome therapy scores phase 3 win
Adcentrx launches Phase 1 study for its next-generation ADC...
BrainChild Bio advances development of CAR T therapy for pediatric...
Orbis Medicines bags €90 million Series A to develop oral...
Teva and Sanofi’s IBD drug hits Phase 2 targets
Orexo and Abera collaborate to develop nasal powder vaccines
→
→
→
→